Xtandi During AS Reduced Progression Risk in Early Prostate Cancer

(MedPage Today) -- Patients with low- or intermediate-risk localized prostate cancer who received enzalutamide (Xtandi) monotherapy saw a reduced risk of cancer progression, according to a randomized phase II trial.
Among 227 patients on active...